Phase II study of cetuximab plus 5-FU/LV for unresectable colorectal cancer
Phase 2
- Conditions
- nresectable colorectal cancer
- Registration Number
- JPRN-UMIN000009483
- Lead Sponsor
- Aichi Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Symptomatic brain metastasis Sever wattery diarrhea Paralytic or mechanical bowel obstruction Confirmed or suspected infection Severe pulmonary disease Severe comorbidity Pregnant or possibly pregnant, and nursing women Sever neurologic disease Receiving atazanavir sulfate Past history of monoclonal antibody sever allergy Past history of 5-FU/LV sever allergy Past history of treatment with Anti-EGFR Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method disease control rate, progression free survival, overall survival, toxicity, QO